Search

Displaying results 2421 - 2430 of 10000 in total
  1. Drug

    Warfarin

    go.drugbank.com/drugs/DB00682
    ApprovedInvestigational

    Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. … Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Pyrophosphoric acid

    go.drugbank.com/drugs/DB04160
    ApprovedInvestigational

    Mixtures: Exoden All In One
  3. Drug

    Gemcitabine

    go.drugbank.com/drugs/DB00441
    ApprovedInvestigational

    It is approved by the FDA to treat advanced ovarian cancer in combination with [carboplatin], metastatic breast cancer in combination with [paclitaxel], non-small cell lung cancer in combination with [ … [L32950] It is also being investigated in other cancer and tumour types.

  4. Drug

    Treosulfan

    go.drugbank.com/drugs/DB11678
    ApprovedInvestigational

    [L52245] It was approved by the EMA in June 2019[L16965] and by the FDA in January 2025 for use in combination with [fludarabine].[L52575]

  5. Drug

    Chloroquine

    go.drugbank.com/drugs/DB00608
    ApprovedInvestigationalVet approved

    Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. … [A192432] **The FDA emergency use authorization for [hydroxychloroquine] and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.

  6. Drug

    Belumosudil

    go.drugbank.com/drugs/DB16703
    ApprovedInvestigational

    [A236634] It is an inhibitor of rho-associated coiled-coil-containing protein kinases (ROCK), with significantly more selectivity for ROCK2 as compared to ROCK1 (IC<sub>50</sub> 100 nM vs. 3 μM, respectively … [L34754] In July 2022, Belumosudil was approved by Health Canada under the brand name RHOLISTIQ to treat the same condition in adult and pediatric patients 12 years or older.[L42925]

  7. Drug

    Idecabtagene vicleucel

    go.drugbank.com/drugs/DB16665
    ApprovedInvestigational

    [L32858] Idecabtagene vicleucel was approved by the FDA on March 26, 2021 [L32863] and by the EMA on August 18, 2021.[L51003] … [A232563] Multiple myeloma is typically treated with an immunomodulatory agent like [lenalidomide],[A232593] a proteasome inhibitor like [bortezomib], or an anti-CD38 monoclonal antibody like [isatuximab

  8. Drug

    Dronedarone

    go.drugbank.com/drugs/DB04855
    ApprovedInvestigational

    [T28] Commonly marketed as Multaq®, dronedarone was approved by the FDA in July 2009 and Health Canada in August 2009. … Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management.

    Synonyms: N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide, N-(2-butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide
  9. Drug

    Carbocromen

    go.drugbank.com/drugs/DB13279
    ApprovedWithdrawn

    Carbocromen was marketed for use in Germany as a vasodilator, however, it has been discontinued due to the risk of arrhythmia development [L5635].

    Categories: Vasodilators Used in Cardiac Diseases
  10. Drug

    Delamanid

    go.drugbank.com/drugs/DB11637
    ApprovedInvestigational

    It is used in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis (TB) in a combination regimen. … In a clinical study involving patients with pulmonary multidrug-resistant tuberculosis or extensively drug-resistant tuberculosis, treatment of delamanid in combination with WHO-recommended optimised background